Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group

J Brown, D Buckley, A Coulthard, A K Dixon, J M Dixon, D F Easton, R A Eeles, D G Evans, Fiona Jane Gilbert, M Graves, C Hayes, J P Jenkins, A P Jones, S F Keevil, M O Leach, G P Liney, S M Moss, A R Padhani, G J Parker, L J Pointon & 6 others B A Ponder, Thomas William Redpath, J P Sloane, L W Turnbull, L G Walker, R M Warren

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation.
Original languageEnglish
Pages (from-to)765-76
Number of pages12
JournalMagnetic Resonance Imaging
Volume18
Issue number7
Publication statusPublished - 1 Sep 2000

Fingerprint

Magnetic resonance
Magnetic resonance imaging
Multicenter Studies
Screening
Breast
Mammography
Magnetic Resonance Imaging
Breast Neoplasms
Imaging techniques
Pathology
Quality assurance
X-Rays
Sensitivity and Specificity
Cytology
X rays
Pharmacokinetics
Contrast Media
Cell Biology
Therapeutics
Kinetics

Keywords

  • Adult
  • Breast Neoplasms
  • Cohort Studies
  • Contrast Media
  • Female
  • Genetic Predisposition to Disease
  • Great Britain
  • Humans
  • Magnetic Resonance Imaging
  • Mammography
  • Mass Screening
  • Middle Aged
  • Radiographic Image Enhancement
  • Sensitivity and Specificity

Cite this

Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. / Brown, J; Buckley, D; Coulthard, A; Dixon, A K; Dixon, J M; Easton, D F; Eeles, R A; Evans, D G; Gilbert, Fiona Jane; Graves, M; Hayes, C; Jenkins, J P; Jones, A P; Keevil, S F; Leach, M O; Liney, G P; Moss, S M; Padhani, A R; Parker, G J; Pointon, L J; Ponder, B A; Redpath, Thomas William; Sloane, J P; Turnbull, L W; Walker, L G; Warren, R M.

In: Magnetic Resonance Imaging, Vol. 18, No. 7, 01.09.2000, p. 765-76.

Research output: Contribution to journalArticle

Brown, J, Buckley, D, Coulthard, A, Dixon, AK, Dixon, JM, Easton, DF, Eeles, RA, Evans, DG, Gilbert, FJ, Graves, M, Hayes, C, Jenkins, JP, Jones, AP, Keevil, SF, Leach, MO, Liney, GP, Moss, SM, Padhani, AR, Parker, GJ, Pointon, LJ, Ponder, BA, Redpath, TW, Sloane, JP, Turnbull, LW, Walker, LG & Warren, RM 2000, 'Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group', Magnetic Resonance Imaging, vol. 18, no. 7, pp. 765-76.
Brown, J ; Buckley, D ; Coulthard, A ; Dixon, A K ; Dixon, J M ; Easton, D F ; Eeles, R A ; Evans, D G ; Gilbert, Fiona Jane ; Graves, M ; Hayes, C ; Jenkins, J P ; Jones, A P ; Keevil, S F ; Leach, M O ; Liney, G P ; Moss, S M ; Padhani, A R ; Parker, G J ; Pointon, L J ; Ponder, B A ; Redpath, Thomas William ; Sloane, J P ; Turnbull, L W ; Walker, L G ; Warren, R M. / Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. In: Magnetic Resonance Imaging. 2000 ; Vol. 18, No. 7. pp. 765-76.
@article{0218375074774b74b5d515b188e65afa,
title = "Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group",
abstract = "The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation.",
keywords = "Adult, Breast Neoplasms, Cohort Studies, Contrast Media, Female, Genetic Predisposition to Disease, Great Britain, Humans, Magnetic Resonance Imaging, Mammography, Mass Screening, Middle Aged, Radiographic Image Enhancement, Sensitivity and Specificity",
author = "J Brown and D Buckley and A Coulthard and Dixon, {A K} and Dixon, {J M} and Easton, {D F} and Eeles, {R A} and Evans, {D G} and Gilbert, {Fiona Jane} and M Graves and C Hayes and Jenkins, {J P} and Jones, {A P} and Keevil, {S F} and Leach, {M O} and Liney, {G P} and Moss, {S M} and Padhani, {A R} and Parker, {G J} and Pointon, {L J} and Ponder, {B A} and Redpath, {Thomas William} and Sloane, {J P} and Turnbull, {L W} and Walker, {L G} and Warren, {R M}",
year = "2000",
month = "9",
day = "1",
language = "English",
volume = "18",
pages = "765--76",
journal = "Magnetic Resonance Imaging",
issn = "0730-725X",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group

AU - Brown, J

AU - Buckley, D

AU - Coulthard, A

AU - Dixon, A K

AU - Dixon, J M

AU - Easton, D F

AU - Eeles, R A

AU - Evans, D G

AU - Gilbert, Fiona Jane

AU - Graves, M

AU - Hayes, C

AU - Jenkins, J P

AU - Jones, A P

AU - Keevil, S F

AU - Leach, M O

AU - Liney, G P

AU - Moss, S M

AU - Padhani, A R

AU - Parker, G J

AU - Pointon, L J

AU - Ponder, B A

AU - Redpath, Thomas William

AU - Sloane, J P

AU - Turnbull, L W

AU - Walker, L G

AU - Warren, R M

PY - 2000/9/1

Y1 - 2000/9/1

N2 - The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation.

AB - The imaging and analysis protocol of the UK multicentre study of magnetic resonance imaging (MRI) as a method of screening for breast cancer in women at genetic risk is described. The study will compare the sensitivity and specificity of contrast-enhanced MRI with two-view x-ray mammography. Approximately 500 women below the age of 50 at high genetic risk of breast cancer will be recruited per year for three years, with annual MRI and x-ray mammography continuing for up to 5 years. A symptomatic cohort will be measured in the first year to ensure consistent reporting between centres. The MRI examination comprises a high-sensitivity three-dimensional contrast-enhanced assessment, followed by a high-specificity contrast-enhanced study in equivocal cases. Multiparametric analysis will encompass morphological assessment, the kinetics of contrast agent uptake and determination of quantitative pharmacokinetic parameters. Retrospective analysis will identify the most specific indicators of malignancy. Sensitivity and specificity, together with diagnostic performance, diagnostic impact and therapeutic impact will be assessed with reference to pathology, follow-up and changes in diagnostic certainty and therapeutic decisions. Mammography, lesion localisation, pathology and cytology will be performed in accordance with the UK NHS Breast Screening Programme quality assurance standards. Similar standards of quality assurance will be applied for MR measurements and evaluation.

KW - Adult

KW - Breast Neoplasms

KW - Cohort Studies

KW - Contrast Media

KW - Female

KW - Genetic Predisposition to Disease

KW - Great Britain

KW - Humans

KW - Magnetic Resonance Imaging

KW - Mammography

KW - Mass Screening

KW - Middle Aged

KW - Radiographic Image Enhancement

KW - Sensitivity and Specificity

M3 - Article

VL - 18

SP - 765

EP - 776

JO - Magnetic Resonance Imaging

JF - Magnetic Resonance Imaging

SN - 0730-725X

IS - 7

ER -